Coloplast A/S (OTCMKTS:CLPBY) Announces Earnings Results, Misses Estimates By $0.01 EPS

Coloplast A/S (OTCMKTS:CLPBY) released its earnings results on Tuesday. The company reported $0.07 EPS for the quarter, missing the consensus estimate of $0.08 by ($0.01), Zacks reports. Coloplast A/S had a net margin of 18.69% and a return on equity of 30.19%. Coloplast A/S updated its FY 2025 guidance to EPS.

Coloplast A/S Stock Up 0.4 %

OTCMKTS CLPBY opened at $11.18 on Thursday. Coloplast A/S has a 1-year low of $10.63 and a 1-year high of $14.34. The company has a quick ratio of 0.66, a current ratio of 1.02 and a debt-to-equity ratio of 0.92. The stock’s 50 day moving average is $11.43 and its two-hundred day moving average is $12.56.

Coloplast A/S Increases Dividend

The firm also recently declared a dividend, which was paid on Friday, December 20th. Shareholders of record on Monday, December 9th were paid a dividend of $0.2435 per share. This is a boost from Coloplast A/S’s previous dividend of $0.05. The ex-dividend date was Monday, December 9th. Coloplast A/S’s dividend payout ratio (DPR) is currently 93.94%.

Analyst Ratings Changes

Several research firms recently weighed in on CLPBY. UBS Group upgraded shares of Coloplast A/S from a “strong sell” rating to a “hold” rating in a research note on Wednesday, December 11th. Hsbc Global Res upgraded Coloplast A/S from a “moderate sell” rating to a “hold” rating in a research report on Monday, November 18th. Finally, Sanford C. Bernstein upgraded Coloplast A/S from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, January 28th.

About Coloplast A/S

Coloplast A/S engages in the development and sale of intimate healthcare products and services in Denmark, the United States, the United Kingdom, France, and internationally. The company operates through Chronic Care, Continence Care, Voice and Respiratory Care, Interventional Urology, and Advanced Wound Care segments.